Rapid respiratory virus detection
Prodesse, Inc. has received FDA approval for its ProFlu+ Assay test, which simultaneously detects the common respiratory viruses influenza A, influenza B, and respiratory syncytial virus A in a patient's respiratory secretions. The test provides results in as few as 3 hours using real-time polymerase chain reaction technology with a multiplex platform that allows several tests to be processed from the same sample. The test's rapidity allows health care providers to quickly determine whether a respiratory illness is caused by one of these viruses and initiate the appropriate treatment at the most effective times. In clinical tests, ProFlu+ Assay's overall clinical sensitivity and specificity were 98% and 83%, respectively.
Information:http://www.nursingcenter.com/nmie/upfront
Results just a breath away
Apieron, Inc. announced the FDA's approval of its Insight eNO System to assist in the management of patients with asthma. The system measures exhaled nitric oxide, an established indicator of airway inflammation and asthma control. Expressly designed for the health care provider's office, it's noninvasive, safe, easy to use, and provides highly accurate results in less than 1 minute. Apieron's unique disposable, single-use biosensor detects trace amounts of nitric oxide molecules in a single human breath. Disposable single-use breath tubes make the process hygienic and convenient for the user to exhale into the device. The Insight eNO includes a small desktop monitor with an easy-to-read display, trend analysis capabilities, and a user-friendly interface. Patient data can be stored and maintained for trend analysis or downloaded to a printer for insurers' and patients' files.
Information:http://www.nursingcenter.com/nmie/upfront
Dark blue means MRSA
The FDA has approved Thermo Fisher Scientific, Inc.'s Spectra MRSA, a test designed to screen for methicillin-resistant Staphylococcus aureus (MRSA). With the highest positive predictive value commercially available for MRSA screening, the easy-to-read test provides accurate results within 24 hours, with MRSA appearing as distinctive dark blue colonies. This ready-to-use, cost effective, labor-saving device can be adopted in any health care facility to enable continuous testing of patients. The test is manufactured, distributed, and sold under the Thermo Fisher specialty brand Remel.
Information:http://www.nursingcenter.com/nmie/upfront